Palisade Bio (PALI) director receives 336,904 RSUs in equity grant

Rhea-AI Filing Summary

Zwick Jordan Michael reported acquisition or exercise transactions in this Form 4 filing.

Palisade Bio director Jordan Michael Zwick reported receiving a grant of 336,904 shares of Common Stock in the form of Restricted Stock Units as compensation. These RSUs carry a zero dollar grant price and will vest in three equal annual installments starting on June 10, 2026, contingent on his continued service with the company. After this award, the filing shows Zwick holding 336,904 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zwick Jordan Michael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	336,904	$0.00	--

Holdings After Transaction: Common Stock — 336,904 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 336,904 shares Grant price per share: $0.0000 per share Shares held after transaction: 336,904 shares

3 metrics

RSUs granted 336,904 shares Restricted Stock Units granted on June 10, 2026 vesting start

Grant price per share $0.0000 per share Equity compensation, not an open-market purchase

Shares held after transaction 336,904 shares Total direct holdings following RSU award

Key Terms

Restricted Stock Unit ("RSU"), service-based vesting requirement, contingent right to receive

3 terms

Restricted Stock Unit ("RSU") financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock."

service-based vesting requirement financial

"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."

contingent right to receive financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zwick Jordan Michael

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A(1)		336,904	A	(1)	336,904	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.

	/s/ Ryker Willie, Attorney-in-Fact for Jordan Michael Zwick	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Palisade Bio (PALI) director Jordan Michael Zwick report in this Form 4?

He reported an acquisition of 336,904 shares of Palisade Bio common stock through a Restricted Stock Unit (RSU) grant. The award is compensation-based, not an open-market purchase, and carries a zero dollar grant price per share.

How many Palisade Bio (PALI) RSUs were granted to Jordan Michael Zwick?

The filing shows a grant of 336,904 RSUs, each representing a right to receive one share of common stock. These units form part of his equity compensation and increase his direct reported holdings to 336,904 shares after the transaction.

What is the vesting schedule for Jordan Michael Zwick’s RSUs at Palisade Bio (PALI)?

The RSUs vest in three equal annual installments, beginning on the anniversary of June 10, 2026. Vesting is subject to his continuous service with Palisade Bio through each vesting date, meaning unvested units can be forfeited if service ends.

Is Jordan Michael Zwick’s Palisade Bio (PALI) RSU grant an open-market stock purchase?

No, the Form 4 describes a grant/award acquisition, not an open-market buy. The transaction code is “A” and the price per share is reported as $0.0000, indicating equity compensation rather than a cash purchase on the market.

How many Palisade Bio (PALI) shares does Jordan Michael Zwick hold after this RSU grant?

Following the reported transaction, his total direct holdings are shown as 336,904 shares of Palisade Bio common stock. This total reflects the newly granted Restricted Stock Units as reported in the Form 4 filing.

What does a Restricted Stock Unit (RSU) mean in Palisade Bio (PALI)’s Form 4 filing?

Each RSU represents a contingent right to receive one share of Palisade Bio common stock. The units convert into shares only as they vest over time, subject to service-based conditions outlined in the director’s compensation agreement.